苏州兰鼎生物制药

Suzhou Landing Biological Pharmaceutical is a Chinese biotechnology company focused on the development of long-acting recombinant protein therapeutics. The company leverages a proprietary Human Serum Albumin (HSA) fusion platform to significantly extend the half-life of protein and peptide drugs, reducing dosing frequency and improving patient compliance. Its primary R&D efforts are concentrated on metabolic diseases, infectious diseases, and oncology supportive care. Landing Bio operates integrated facilities in the Suzhou Industrial Park that encompass research, clinical development, and GMP-compliant manufacturing. The company's lead assets include long-acting versions of GLP-1 for diabetes and Interferon-alpha for viral hepatitis.